Pembrolizumab Combos Miss Primary Endpoints in Liver, Prostate Cancer Trials
The LEAP-002 study evaluated pembrolizumab plus lenvatinib in patients with uHCC; the KEYNOTE-921 study evaluated pembrolizumab plus docetaxel in patients with mCRPC.
The LEAP-002 study evaluated pembrolizumab plus lenvatinib in patients with uHCC; the KEYNOTE-921 study evaluated pembrolizumab plus docetaxel in patients with mCRPC.
Increase in screening differed by age, with 19.4 percent increase for those aged 50 to 54 and 31.6 percent increase for those aged 70 to 75
Significant reduction seen in risk of prostate cancer progression for enzalutamide plus AS versus active surveillance alone
However, association does not hold for nondairy calcium intake
The sNDA is supported by data from the phase 3 ARASENS trial, which included1306 patients with mHSPC.
Camcevi is a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, a gonadotropin-releasing hormone agonist.
Pluvicto is a radioligand therapeutic agent containing the active moiety, lutetium-177, which binds to PSMA, a transmembrane protein that is expressed in prostate cancer.
Following a planned interim analysis, the decision to halt the trial was made after a review of data by an independent Data Monitoring Committee.
No significant associations seen for spironolactone with risk for breast, ovarian, bladder, kidney, gastric, esophageal cancers
The phase 3 MAGNITUDE study assessed niraparib in combination with abiraterone acetate plus prednisone in patients with mCRPC with or without alterations in homologous recombination repair associated genes.